New Non-Executive Director appointed at Oxford Biomedica

Gene and cell therapy group Oxford Biomedica has announced the appointment of Leone Patterson as an Independent Non-Executive Director, effective 1 May 2023.

Leone brings more than 20 years’ experience in public biotech companies, including within the cell and gene therapy industry, having overseen growth within international commercial companies working across areas including strategy, finance, operations and governance.

At clinical-stage company Tenya Therapeutics, she is currently the Chief Financial and Business Officer and serves on the Board of Directors for Nkarta, a clinical-stage cell therapy company.

Leone previously held leadership roles, including Chief Executive Officer and Chief Financial Officer, at Adverum Biotechnologies and has also held the role of Chief Financial Officer at public companies, including diagnostics firm Diadexus and speciality pharmaceuticals provider Transcept Pharmaceuticals and, earlier in her career, worked within Novartis, Chiron and KPMG.

Read more - Oxford Biomedica reports full year financial loss

She holds a B.S. in business administration and accounting from Chapman University, an executive M.B.A. from St. Mary's College, and is a Certified Public Accountant (inactive).

Dr. Roch Doliveux, Chair of Oxford Biomedica, said: "The appointment of Leone comes at an important juncture for Oxford Biomedica, as we advance our global leadership in viral vector development and supply, providing innovative solutions to our international biopharma customers.

“Leone's deep understanding of corporate finance, her experience of the US public markets and M&A, in addition to her extensive experience in the cell and gene therapy industry will be invaluable in supporting our international strategy and further strengthening our market position."

Ms Leone Patterson said: "I am honoured to be joining the Board of Oxford Biomedica, a global innovation-led CDMO dedicated to enabling the development of life-saving cell and gene therapies. I look forward to working with the Board and contributing my expertise to help advance the Company's strategy."

Read more - Dr Frank Mathias to join Oxford Biomedica as new CEO